Skip to content. | Skip to navigation

Personal tools


Managing bodies

logo Inserm      logo cnrslogo ENSL       logo ucb1

Secondary managing bodies

logo ENSL logo ucb1

You are here: Home / About us / News / CIRI development is supported by Europe, the French government and local authorities

CIRI development is supported by Europe, the French government and local authorities

The construction of a new building and the renovation of the research building at Université Claude Bernard Lyon 1 on the Gerland site for CIRI were made possible thanks to the 2015-2020 Contrat-Plan Etat Région (CPER), supported in particular by the Metropole of Lyon and CIRI's supervisors.



Delivered in early 2023, the building is now occupied by eight CIRI teams, the Center's support services (Management, Administration, BioInformatics and BioStatistics department), services from the SFR Biosciences Support and Research Unit, as well as its administration and management and the IVPC research unit. 

The name "Rosalind Franklin" has been proposed for the building, in honor of this pioneer of molecular biology. It will be inaugurated in October 2023. 

Support from the AURA region and Europe has made it possible to equip all the research laboratories for CIRI teams, thanks to a grant obtained by Inserm as part of the FEDER-FSE Rhône-Alpes 2014-2020 operational program. The technology platforms managed by UAR SFR Biosciences and housed in the new building have also benefited from support from the region and Europe via the PlExMiCo project obtained by ENS Lyon for the development of Platforms for Experimentation in Confined Environments, which will be open to the entire local and regional scientific community. These platforms will also enable the study of level 2 and 3 infectious pathogens, for example those transmitted by vectors such as insects, or in toto imaging of infected organisms, thanks to specific equipment financed by the EquipEx+ InfectioTron.

CIRI thanks all its funders for the resources they have provided, enabling us to develop rich and diversified research aimed at better understanding and identifying therapeutic solutions for infectious and immune pathologies.